|
Symbol
|
IHTEFG | HZJEFG | RMBFAV | Z09YGZ | PBURCH | RMA3QV | RMBRKV | ERORCH | ABMUTQ | PRZRCH | Z0ARNZ | CQWBKB | PWCRCH | LYXRCH | LYZRCH | LZJRCH | LZMRCH | UJERWU | RMAT9V | RMBGJV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Reverse Convertible | Reverse Convertible | Multi Vonti | Autocallable Reverse Convertible Defensive worst | Worst of Callable Reverse Convertible | Multi Vonti | Reverse Convertible | Worst of Callable Reverse Convertible | Multi Reverse Convertible | Worst of Callable Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Reverse Convertible | Autocallable Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Reverse Convertible | Worst of Reverse Convertible | Worst of Reverse Convertible | GOAL | Reverse Convertible | Multi Vonti |
|
Sous-jacent
|
Compagnie Financière Richemont SA / Lonza Group N / Sonova Hldg. AG / Swiss RE AG / Swisscom N | Lonza Group N / Roche PS / Sika AG | Kühne & Nagel Intl. AG / Lonza Group N / Sika AG | Compagnie Financière Richemont SA / Lonza Group N / Schindler PS / Sika AG | Alcon / Lonza Group N / Sandoz Group AG | Alcon / Lonza Group N / Novartis AG / Roche PS / Sandoz Group AG | Bucher Industries AG / Lonza Group N / Sika AG | BKW AG / Kühne & Nagel Intl. AG / Lonza Group N | Clariant AG / Comet Hldg. AG / Lonza Group N / OC Oerlikon N / Swatch Group I | Lonza Group N / Swiss Life Hldg. N / Swiss RE AG | Holcim/Amrize Basket / Lonza Group N / Sandoz Group AG | Lonza Group N / Novartis AG / Roche PS / Straumann Hldg. AG | Kühne & Nagel Intl. AG / Logitech International SA / Lonza Group N / Swiss RE AG / UBS Group AG | Logitech International SA / Lonza Group N / Partners Group Hldg. AG / Sika AG | Lonza Group N / SGS S.A. Ltd. / Swisscom N | Alcon / Lonza Group N / Novartis AG / Sandoz Group AG / Siegfried Hldg. AG | Holcim AG / Swiss RE AG / Lonza Group N | Bachem Hldg. AG / Lonza Group N / Straumann Hldg. AG | Alcon / Lonza Group N / Partners Group Hldg. AG | Alcon / Lonza Group N / Novartis AG / Straumann Hldg. AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
28.06.2029 | 02.11.2026 | 13.07.2026 | 27.08.2027 | 21.07.2026 | 09.11.2026 | 05.11.2026 | 06.11.2026 | 20.12.2029 | 24.02.2027 | 25.08.2026 | 13.03.2028 | 27.06.2029 | 07.10.2026 | 14.07.2027 | 24.07.2026 | 31.07.2026 | 02.08.2027 | 12.08.2026 | 19.08.2027 |
| Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
176,28 | 182,298 | 208,20 | 179,883 | 57,988 | 56,14 | 197,80 | 100,685 | 6,7665 | 97,965 | 463,386 | 78,705 | 89,05 | 831,20 | 361,14 | 67,425 | 110,6625 | 75,3422 | 828,5956 | 51,80 |
| rendement max. p.a. | - | - | 694,84% | 14,32% | - | 21,74% | 45,02% | 4,06% | 12,30% | 3,96% | 0,56% | 7,02% | 6,93% | 98,11% | 2,14% | 16,58% | -3,55% | 7,89% | 201,43% | 10,35% |
| Demande | 89,91 | 91,85 | 85,20 | - | 95,29 | 94,30 | 89,10 | 99,97 | 80,59 | 99,68 | - | 96,43 | 93,11 | 82,52 | 100,19 | 98,62 | 99,86 | 99,65 | 81,60 | 94,80 |
| Offre | - | - | 86,50 | - | - | 95,30 | 90,30 | 100,77 | 81,39 | 100,48 | - | 97,23 | 93,91 | 83,32 | 100,99 | 99,42 | 100,66 | 100,70 | 82,90 | 95,80 |